Skip to menu Skip to content Skip to footer
Professor Michael Stowasser
Professor

Michael Stowasser

Email: 
Phone: 
+61 7 3176 2694

Overview

Background

MS has 35 years clinical research experience in pathogenesis and management of hypertension (HT), including endocrine varieties such as primary aldosteronism (PA). Working within the Greenslopes Hospital Hypertension Unit (GHHU), he helped demonstrate that PA is 10 times more common than previously thought and to account for approximately 10% of HT, making it the commonest specifically treatable, potentially curable variety, and in the description of a new familial form (FH-II) which recently led to the elucidation of its genetic basis (a gain of function mutation in CLCN2, published in Nature Genetics). The combined GHHU/Princess Alexandra Hospital HT Unit (PAHHU, which MS set up in 2000) has possibly the largest series (>2500) worldwide of patients with PA who have been thoroughly documented and meticulously studied, helping MS to become internationally recognized as an authority on pathogenesis/genetics, diagnostic workup and management of PA. In 2006, MS served as member of an international Task Force sponsored by the US Endocrine Society to develop the first guideline for diagnosis and management of PA (published in J Clin Endocrinol Metab and cited >1200 times with an update published in 2016 and cited >1900 times). He is currently Co-Chair of the working group for the third guideline. MS conceived, developed and validated the seated saline suppression test which has since become the favoured method for definitively confirming the diagnosis of PA in most Australian and in a rapidly growing number of overseas institutions. He has also made major contributions to the understanding of how various physiological and pharmacological factors affect the aldosterone/renin ratio as a screening test for PA and in optimizing approaches to adrenal venous sampling, the most reliable method of differentiating unilateral (surgically curable) from bilateral varieties.

Publications: MS has published 1 book, 20 textbook chapters and >250 papers in peer-reviewed scientific journals. His journal publications have been cited >14,000 times ("h" index 59).

Grant Support: Since 2019, MS has received ~$16 million in research grant support. He is currently a CI on two MRFF grants and an NHMRC CCRE.

Invited Presentations and Collaboration: MS has been invited to speak at major meetings 137 times (99 international) and has collaborated with researchers in >20 international Units and all Australian states. In 2018, was one of six investigators awarded a highly prestigious Leducq Foundation Transatlantic Networks of Excellence Program grant ($USD 6 million) to study the role of potassium in hypertension.

Committee Highlights: MS is past President of the Asian-Pacific Society of Hypertension and of the High Blood Pressure Research Council of Australia. During his time as HBPRCA President, initiatives that were introduced under his presidency included launching of a successful bid for 24h ABPM to be assigned an item number to enable a Medicare rebate of ABPM services. He was a Member of the NHF BP & Vascular Disease Advisory Committee 1998-2013.

Community Engagement: As President since 1995 of the Queensland Hypertension Association, a non-profit organization dedicated to promoting self-care in the management of hypertension, MS has overseen all of its activities, including bimonthly educational sessions and preparation of educational material for the general community and health professionals. On numerous occasions, MS has provided information to the community on issues related to hypertension by media interview.

Peer Review: Previously serving on Editorial Boards for of J Clin Endocrinol Metab, J Hypertens, Clin Exper Pharmacol Physiol, and Nephology, MS is currently Editor-in-Chief of J Hum Hypertens and a member of the Editorial Board for Hypertension. He has assessed 100’s of manuscripts for major international journals and served as grant application assessor on many occasions for major international and national funding bodies (including the NHMRC).

Other Awards and Honours: (1) John W.H. Tyrer Prize for Research in Internal Medicine, (2) Robert Vandongen Memorial Lecturer (University of WA), 2002, (3) Honorary Professor to the Xinjiang Institute of Hypertension, 2005, (4) Visiting Professor to the Tung Wah Eastern Hospital, Hong Kong, 2008, (5) Gaston Bauer Lecturer, Cardiac Society of Australia and New Zealand, 2012, (5) Nimmo Visitor, Royal Adelaide Hospital, 2015, (6) Paul Korner Award, Hypertension Australia, 2024.

Availability

Professor Michael Stowasser is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Medicine Surgery, The University of Queensland
  • Doctor of Philosophy, The University of Queensland
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians

Research interests

  • Determining the genetic basis for FH-II and other forms of primary aldosteronism

  • Improving methods of detection, diagnostic workup and management of primary aldosteronism

  • Validating a highly accurate method of measuring aldosterone using tandem mass spectrometry developed within the EHRC

  • Determining genetic factors which may modify phenotypic expression in FH-I, and thereby explain the wide spectrum of hypertens

  • Determining the extent to which aldosterone excess in humans is capable of causing cardiovascular and other organ dysfunction in

Research impacts

Hypertension (high blood pressure) affects around 30% of Australian adults, and is a leading risk factor for stroke. Treatment usually means lifelong medications, potentially costly and poorly tolerated. However, when the cause can be identified, and reversed or specifically treated, the outcomes are often dramatic with patients being able to come off many or all antihypertensives and enjoying markedly improved quality of life, while at the same time reducing their stroke risk.

The Endocrine Hypertension Research Centre (EHRC), a University of Queensland School of Medicine Centre based at Greenslopes and Princess Alexandra Hospitals, conducts internationally acclaimed research into the causes and management of various forms of hypertension, with a major focus on curable and specifically treatable varieties. It is the only Centre of its kind in Queensland and one of only a few internationally recognized Australian groups dedicated to hypertension-related clinical management and research. An important area of our work, for which the Centre has attracted much attention, has been our detailed studies into epidemiological, biochemical, morphological, pathophysiological and genetic aspects of a potentially curable form of hypertension known as primary aldosteronism (PA), in which the adrenal glands produce excessive amounts of salt retaining hormone (aldosterone). The EHRC demonstrated 20 years ago that PA is approximately ten times more common than previously thought, and accounts for as many as 10% of patients with hypertension. This finding has led to the identification of thousands of patients around the world who would otherwise have gone undetected, and in whom hypertension has been cured or markedly improved following surgical or specific medical treatment. More than 2000 thoroughly studied and documented patients with PA (probably the largest series worldwide) in our Centre provide a unique resource for further research into causes, diagnosis and treatment, and have led to important collaborations with first-class overseas investigators.

Research at the EHRC and elsewhere has shown that aldosterone excess in unrecognised PA is associated with significant cardiovascular morbidity which exceeds that due to hypertension alone. For example, the risk of stroke in PA is over four times higher than that for other forms of hypertension. In one rare familial form of PA, detectable by a genetic test developed in our Centre, hypertension can be particular severe and of early onset, leading to death at ages as young as 30 from hypertensive, haemorrhagic stroke. Because this increase risk is completely reversed by specifically treating the PA condition, it is vitally important that as many patients as possible with PA be identified among the hypertensive population. Major challenges exist in accurate diagnosis of PA, prompting our Centre to research better ways to achieve this, including through genetic testing and enhanced clinical and biochemical approaches, so that more people will be detected and given the opportunity to receive superior, highly effective treatment.

Among its many other projects, the Centre is actively involved in unlocking the genetic and molecular code of another form of hypertension known as Gordon syndrome (named after the Centre’s founder, Richard Gordon) which results in excessive retention of salt and potassium by the kidney. This work has the potentially to greatly enhance our understanding of how the kidney regulates salt balance and blood pressure, and to lead to the development of new drugs to treat hypertension and thereby prevent stroke.

Works

Search Professor Michael Stowasser’s works on UQ eSpace

414 works between 1990 and 2025

61 - 80 of 414 works

2019

Journal Article

Exercise and sport science Australia position stand update on exercise and hypertension

Sharman, James E., Smart, Neil A., Coombes, Jeff S. and Stowasser, Michael (2019). Exercise and sport science Australia position stand update on exercise and hypertension. Journal of Human Hypertension, 33 (12), 837-843. doi: 10.1038/s41371-019-0266-z

Exercise and sport science Australia position stand update on exercise and hypertension

2019

Journal Article

Diagnosis of primary aldosteronism by seated saline suppression test - variability between immunoassay and HPLC-MS/MS

Thuzar, Moe, Young, Karen, Ahmed, Ashraf H., Ward, Greg, Wolley, Martin, Guo, Zeng, Gordon, Richard D., McWhinney, Brett C., Ungerer, Jacobus P. and Stowasser, Michael (2019). Diagnosis of primary aldosteronism by seated saline suppression test - variability between immunoassay and HPLC-MS/MS. Journal of Clinical Endocrinology and Metabolism, 105 (3) dgz150, e477-e483. doi: 10.1210/clinem/dgz150

Diagnosis of primary aldosteronism by seated saline suppression test - variability between immunoassay and HPLC-MS/MS

2019

Journal Article

Response to letter to the editor: "Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism"

Stowasser, Michael, Guo, Zeng, Ahmed, Ashraf, Wolley, Martin and Gordon, Richard D. (2019). Response to letter to the editor: "Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism". The Journal of Clinical Endocrinology and Metabolism, 104 (6), 2344-2345. doi: 10.1210/jc.2019-00179

Response to letter to the editor: "Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism"

2019

Journal Article

Pathogenesis of familial hyperaldosteronism type II: new concepts involving anion channels

Stowasser, Michael, Wolley, Martin, Wu, Aihua, Gordon, Richard D., Schewe, Julia, Stoelting, Gabriel and Scholl, Ute I. (2019). Pathogenesis of familial hyperaldosteronism type II: new concepts involving anion channels. Current Hypertension Reports, 21 (4) 31, 31. doi: 10.1007/s11906-019-0934-y

Pathogenesis of familial hyperaldosteronism type II: new concepts involving anion channels

2019

Journal Article

Mineralocorticoid antagonism enhances brown adipose tissue function in humans: a randomized placebo-controlled cross-over study

Thuzar, Moe, Law, W. Phillip, Dimeski, Goce, Stowasser, Michael and Ho, Ken K. Y. (2019). Mineralocorticoid antagonism enhances brown adipose tissue function in humans: a randomized placebo-controlled cross-over study. Diabetes, Obesity and Metabolism, 21 (3), 509-516. doi: 10.1111/dom.13539

Mineralocorticoid antagonism enhances brown adipose tissue function in humans: a randomized placebo-controlled cross-over study

2019

Journal Article

The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway

Wu, Aihua, Wolley, Martin and Stowasser, Michael (2019). The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway. Journal of Human Hypertension, 33 (7), 508-523. doi: 10.1038/s41371-019-0170-6

The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway

2019

Conference Publication

Improving hypertension control by molecular stratification of first-line non-responders using RAAS triple-A testing

Poglitsch, M., Ahmed, A. H., Guo, Z., Burrello, J., Stoller, A., Burkard, T., Domenig, O., Haschke, M., Mulatero, P. and Stowasser, M. (2019). Improving hypertension control by molecular stratification of first-line non-responders using RAAS triple-A testing. 29th European Meeting of Hypertension and Cardiovascular Protection of the European-Society-of-Hypertension (ESH), Milan Italy, 21-24 June 2019. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1097/01.hjh.0000572980.98621.b4

Improving hypertension control by molecular stratification of first-line non-responders using RAAS triple-A testing

2019

Conference Publication

ACE-S: a novel angiotensin based marker for monitoring prarmacologic activity of ACE inhibitors in hypertensive patients

Domenig, O., Ahmed, A. H., Guo, Z., Stoller, A., Burkard, T., Haschke, M., Stowasser, M. and Poglitsch, M. (2019). ACE-S: a novel angiotensin based marker for monitoring prarmacologic activity of ACE inhibitors in hypertensive patients. 29th European Meeting of Hypertension and Cardiovascular Protection of the European-Society-of-Hypertension (ESH), Milan, Italy, 21-24 June 2019. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1097/01.hjh.0000570640.20346.d4

ACE-S: a novel angiotensin based marker for monitoring prarmacologic activity of ACE inhibitors in hypertensive patients

2019

Conference Publication

Defining the optimal cut-off plasma aldosterone level measured by immunoassay for the diagnosis of primary aldosteronism using seated salines suppression test

Thuzar, M., Young, K., Ahmed, A., Wolley, M., Guo, Z., Ward, G., McWhinney, B., Ungerer, J. and Stowasser, M. (2019). Defining the optimal cut-off plasma aldosterone level measured by immunoassay for the diagnosis of primary aldosteronism using seated salines suppression test. 29th European Meeting of Hypertension and Cardiovascular Protection of the European-Society-of-Hypertension (ESH), Milan, Italy, 21-24 June 2019. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1097/01.hjh.0000570272.55373.54

Defining the optimal cut-off plasma aldosterone level measured by immunoassay for the diagnosis of primary aldosteronism using seated salines suppression test

2019

Book Chapter

Primary aldosteronism; epidemiology and screening

Stowasser, Michael (2019). Primary aldosteronism; epidemiology and screening. Encyclopedia of endocrine diseases. (pp. 598-606) edited by Ilpo Huhtaniemi and Luciano Martini. Amsterdam, Netherlands: Elsevier. doi: 10.1016/B978-0-12-801238-3.64331-3

Primary aldosteronism; epidemiology and screening

2019

Conference Publication

The effect of rampiril on the aldosterone/renin ratio and aldosterone/andiotensin II ratio in patients with primary aldosteronism: a pilot study

Guo, Z., Cowley, D., Poglitsch, M., McWhinney, B., Ungerer, J., Wolley, M. and Stowasser, M. (2019). The effect of rampiril on the aldosterone/renin ratio and aldosterone/andiotensin II ratio in patients with primary aldosteronism: a pilot study. 29th European Meeting of Hypertension and Cardiovascular Protection of the European-Society-of-Hypertension (ESH), Milan, Italy, 21-24 June 2019. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1097/01.hjh.0000570668.96581.d2

The effect of rampiril on the aldosterone/renin ratio and aldosterone/andiotensin II ratio in patients with primary aldosteronism: a pilot study

2018

Journal Article

Aldosterone LC-MS/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism

Guo, Zeng, Poglitsch, Marko, McWhinney, Brett C., Ungerer, Jacobus P. J., Ahmed, Ashraf H., Gordon, Richard D., Wolley, Martin and Stowasser, Michael (2018). Aldosterone LC-MS/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism. Journal of Clinical Endocrinology and Metabolism, 103 (11), 3965-3973. doi: 10.1210/jc.2018-01041

Aldosterone LC-MS/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism

2018

Journal Article

Cellular and genetic causes of idiopathic hyperaldosteronism

Omata, Kei, Satoh, Fumitoshi, Morimoto, Ryo, Ito, Sadayoshi, Yamazaki, Yuto, Nakamura, Yasuhiro, Anand, Sharath K., Guo, Zeng, Stowasser, Michael, Sasano, Hironobu, Tomlins, Scott A. and Rainey, William E. (2018). Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension, 72 (4), 874-880. doi: 10.1161/HYPERTENSIONAHA.118.11086

Cellular and genetic causes of idiopathic hyperaldosteronism

2018

Journal Article

Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism

Stowasser, Michael, Ahmed, Ashraf H., Cowley, Diane, Wolley, Martin, Guo, Zeng, McWhinney, Brett C., Ungerer, Jacobus P. and Gordon, Richard D. (2018). Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism. The Journal of Clinical Endocrinology and Metabolism, 103 (11), 4113-4124. doi: 10.1210/jc.2018-01394

Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism

2018

Journal Article

A young man with severe hypertension

Tan, Jin Ern, Wu, Danielle and Stowasser, Michael (2018). A young man with severe hypertension. BMJ, 362 k2935, k2935. doi: 10.1136/bmj.k2935

A young man with severe hypertension

2018

Journal Article

Is it time to screen all patients with hypertension for primary aldosteronism?

Yang, Jun, Fuller, Peter J. and Stowasser, Michael (2018). Is it time to screen all patients with hypertension for primary aldosteronism?. Medical Journal of Australia, 209 (2), 57-59. doi: 10.5694/mja17.00783

Is it time to screen all patients with hypertension for primary aldosteronism?

2018

Journal Article

Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism

Williams, Tracy A., Burrello, Jacopo, Sechi, Leonardo A., Fardella, Carlos E., Matrozova, Joanna, Adolf, Christian, Baudrand, René, Bernardi, Stella, Beuschlein, Felix, Catena, Cristiana, Doumas, Michalis, Fallo, Francesco, Giacchetti, Gilberta, Heinrich, Daniel A., Saint-Hilary, Gaëlle, Jansen, Pieter M., Januszewicz, Andrzej, Kocjan, Tomaz, Nishikawa, Tetsuo, Quinkler, Marcus, Satoh, Fumitoshi, Umakoshi, Hironobu, Widimský, Jiří, Hahner, Stefanie, Douma, Stella, Stowasser, Michael, Mulatero, Paolo and Reincke, Martin (2018). Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension, 72 (3), HYPERTENSIONAHA.118.11382-649. doi: 10.1161/HYPERTENSIONAHA.118.11382

Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism

2018

Conference Publication

Effect of mineralocorticoid blockade on human brown fat-a randomised placebo-controlled cross-over study

Thuzar, Moe, Law, W. Phillip, Dimeski, Goce, Stowasser, Michael and Ho, Ken K. Y. (2018). Effect of mineralocorticoid blockade on human brown fat-a randomised placebo-controlled cross-over study. Joint Annual Scientific Meetings of Endocrine-Society-of-Australia (ESA) and Society-for-Reproductive-Biology (SRB), Perth Australia, Aug 27-30, 2017. HOBOKEN: WILEY.

Effect of mineralocorticoid blockade on human brown fat-a randomised placebo-controlled cross-over study

2018

Journal Article

CLCN2 chloride channel mutations in familial hyperaldosteronism type II

Scholl, Ute I., Stölting, Gabriel, Schewe, Julia, Thiel, Anne, Tan, Hua, Nelson-Williams, Carol, Vichot, Alfred A., Jin, Sheng Chih, Loring, Erin, Untiet, Verena, Yoo, Taekyeong, Choi, Jungmin, Xu, Shengxin, Wu, Aihua, Kirchner, Marieluise, Mertins, Philipp, Rump, Lars C., Onder, Ali Mirza, Gamble, Cory, McKenney, Daniel, Lash, Robert W., Jones, Deborah P., Chune, Gary, Gagliardi, Priscila, Choi, Murim, Gordon, Richard, Stowasser, Michael, Fahlke, Christoph and Lifton, Richard P. (2018). CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nature Genetics, 50 (3), 1-6. doi: 10.1038/s41588-018-0048-5

CLCN2 chloride channel mutations in familial hyperaldosteronism type II

2017

Journal Article

ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II)

De Sousa, S. M. C., Stowasser, M., Feng, J., Schreiber, A. W., Wang, P., Hahn, C. N., Gordon, R. D., Torpy, D. J., Scott, H. S. and Gagliardi, L. (2017). ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II). Journal of Human Hypertension, 31 (12), 857-859. doi: 10.1038/jhh.2017.71

ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II)

Funding

Current funding

  • 2024 - 2025
    Optimising the Diagnosis and Management of Unilateral Primary Aldosteronism (MSH SERTA Grant led by Metro South HHS)
    Metro South Hospital and Health Service
    Open grant
  • 2023 - 2027
    The CONSEP trial: Implementing screening for a hidden cause of hypertension (2021 MRFF CTA led by Monash University)
    Monash University
    Open grant
  • 2011 - 2030
    Causes, diagnosis and management of hypertension in its various forms
    The Irene Patricia Hunt Memorial Trust
    Open grant

Past funding

  • 2020 - 2023
    Screening for Primary Aldosteronism: Outcomes, Economics and Biomarkers (NHMRC Ideas Grant led by Monash University)
    Monash University
    Open grant
  • 2019 - 2021
    Defining the Novel Effects of Mineralocorticoid Receptor Antagonism on Adiposity and Glucose Homeostatis - A Randomised Controlled Trial
    Diabetes Australia Research Program
    Open grant
  • 2018 - 2023
    Potassium in Hypertension
    Fondation Leducq
    Open grant
  • 2015 - 2017
    A novel approach to streamlining the diagnosis of primary aldosteronism
    NHMRC Project Grant
    Open grant
  • 2014
    High throughput gene expression of patient samples via the Nanostring nCounter system
    UQ Major Equipment and Infrastructure
    Open grant
  • 2013
    Genetic basis of primary aldosteronism as a potentially curable form of hypertension
    PA Research Foundation
    Open grant
  • 2013 - 2017
    Targeted LOWering of Central Blood Pressure in patients with hypertension: a randomised controlled trial (The LOW CBP study) NHMRC Project Grant administered by University of Tasmania
    University of Tasmania
    Open grant
  • 2012
    Elucidating genetic mechanisms responsible for familial hyperaldosteronism type II
    PA Research Foundation Private Practice Trust Fund Research Support Grants
    Open grant
  • 2012 - 2013
    Finding better ways to detect curable hypertension
    PA Research Foundation Private Practice Trust Fund Research Support Grants
    Open grant
  • 2011 - 2012
    Effect of adrenalectomy and spironolactone in the severity of obstructive sleep apnoea in patients with primary aldosteronism
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 2010 - 2013
    Elucidating genetic mechanisms responsible for familial hyperaldosteronism type II
    NHMRC Project Grant
    Open grant
  • 2009 - 2012
    Mayne Bequest Fund Research Support Award: Clinical, pathological and genetic aspects of primary aldosteronism
    Mayne Bequest Fund
    Open grant
  • 2009 - 2010
    Elucidating genetic mechanisms responsible for familial hyperaldosteronism type II
    UQ External Support Enabling Grant
    Open grant
  • 2009 - 2012
    Value of central Blood Pressure for GUIDing managEment of hypertension (BP GUIDE Study)
    NHMRC Project Grant
    Open grant
  • 2008 - 2009
    Elucidating genetic mechanisms responsible for familial hyperaldosteronism type II
    The Endocrine Society (USA)
    Open grant
  • 2007
    Genetics of Primary aldosteronism
    PA Research Foundation
    Open grant
  • 2006 - 2008
    Trial of Aldosterone Blockade and Exercise Training for the Treatment of Exercise Intolerance in Hypertensive Heart Disease
    National Heart Foundation of Australia
    Open grant
  • 2005 - 2007
    Genetics of Primary Aldosteronism
    NHMRC Project Grant
    Open grant
  • 2005
    PAHF block funding
    PA Research Foundation
    Open grant
  • 2003 - 2007
    Centre of Clinical Research Excellence in Cardiovascular Disease and Metabolic Disorders
    NHMRC Research Centre Grant
    Open grant
  • 2002 - 2003
    Biochemical, structural and functional effects of treating fibrosis in hypertensive heart disease
    National Heart Foundation of Australia
    Open grant
  • 2002 - 2003
    Non-BP dependent adverse cardiovascular effects and genetic aspects of aldosterone excess
    National Heart Foundation of Australia
    Open grant
  • 2001 - 2002
    Investigation of the role of the renin-angiotensin system in hepatic fibrosis
    Mayne Bequest Fund
    Open grant
  • 2001 - 2002
    Genetic and therapeutic aspects of familial forms of primary aldosteronism
    Viertel Foundation (Sylvia and Charles Viertel)
    Open grant
  • 2001
    Genetic studies into familial forms of primary aldosteronism
    Princess Alexandra Hospital R&D Foundation
    Open grant
  • 2000 - 2001
    Genetic and phenotypic aspects of familial forms of primary aldosteronism
    UQ New Staff Research Start-Up Fund
    Open grant
  • 2000 - 2001
    Genetic and therapeutic aspects of familial hyperaldosteronism types I and II
    National Heart Foundation of Australia
    Open grant
  • 2000
    The Irene Hunt Hypertension Research Project(s)
    The Irene Patricia Hunt Memorial Trust
    Open grant
  • 1998 - 1999
    Genetic Factors Influencing Aldosterone Biosynthesis and Phenotypic Expression in FH-I
    National Heart Foundation of Australia
    Open grant
  • 1998
    Genetic Factors Influencing Aldosterone Biosynthesis and Phenotypic Expression in PH-1
    Mayne Bequest Fund
    Open grant
  • 1998 - 1999
    Molecular Biology of Familial Hyperaldosteronism Type II
    National Heart Foundation of Australia
    Open grant
  • 1997
    Contribution by wild type and hybrid genes to aldosterone biosynthesis in FH-I
    Mayne Bequest Fund
    Open grant
  • 1996
    Curable hypertension in veterans and others attending Greenslopes Hospital
    Department of Veterans' Affairs
    Open grant
  • 1996 - 1997
    Genetic basis of variable biochemical and clinical phenotypes in familial hyperaldosteronism Type 1
    National Heart Foundation of Australia
    Open grant
  • 1995 - 1997
    An Australian Register for familial hyperaldosteronism - Fellowship
    National Heart Foundation of Australia
    Open grant

Supervision

Availability

Professor Michael Stowasser is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Defining The Role Of Mineralocorticoid Receptor In Cardiometabolic Health & Inflammation & Optimising The Diagnostic Approach For Aldosterone-producing Adenoma

    Principal Advisor

    Other advisors: Dr Moe Thuzar

  • Doctor Philosophy

    Defining The Role Of Mineralocorticoid Receptor In Cardiometabolic Health & Inflammation & Optimising The Diagnostic Approach For Aldosterone-producing Adenoma

    Principal Advisor

    Other advisors: Dr Moe Thuzar

Completed supervision

Media

Enquiries

Contact Professor Michael Stowasser directly for media enquiries about:

  • Aldosteronism - primary
  • Cardiac irregularities
  • High blood pressure
  • Hyperaldosteronism
  • Hypertension
  • Hypertension - familial forms
  • Pathophysiology
  • Phaeochromolytoma
  • Renal artery sterosis

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au